Medtronic gains expanded FDA clearance for snoring implants; Genova Diagnostics buys Metametrix;

@MarkHFierce: We have extended the nomination deadline for the 15 fiercest medical device developers to July 13. Spread the word. Survey | Follow @MarkHFierce

> The FDA granted expanded clearance of Medtronic ($MDT) implants used to treat snoring. Release

> Genova Diagnostics has purchased Metametrix. The combined entity focuses on diagnostics testing for a variety of conditions, including auto-immune disease, diabetes, irritable bowel syndrome, nutritional insufficiencies and metabolic disorders. Financial terms were not disclosed. Release

> Devicemaker Obagi filed an 8k, removing its "poison pill" and clearing the way for an acquisition. Analysts have speculated the company may be targeted by Valeant Pharmaceuticals ($VRX) and Allergan ($AGN), among others. Story

> MiCardia is spinning off its transcatheter tech into a new company, ValCare, using $8 million from a private investor to launch the firm. Release

> Gold Standard Diagnostics secured 510(k) clearance for its Helicobacter pylori enzyme assay, designed to test for the virus that can lead to gastric cancer and peptic ulcer disease. More

> Flexible Stenting Solutions won 510(k) clearance for additional sizes for its FlexStent biliary self-expanding stent system. Release

> Molecular diagnostics company Great Basin Corporation is ramping up its U.S. and European sales efforts, following the FDA's 510(k) clearance in May of its test for the Clostridium difficile infection. Release

Biotech News

 @FierceBiotech: Eli Lilly aims to up  game. Item | Follow @FierceBiotech

 @JohnCFierce:  In latest R&D setback, Lilly's schizophrenia drug flunks a PhIII (and yes, it is a big deal). More | Follow @JohnCFierce

 @RyanMFierce:  Interesting to see ‪genomics‬ firm 23andMe build ‪social web‬ presence with CureTogether buyout. More | Follow @RyanMFierce

> Edmond de Rothschild scores $152M for its fourth biotech fund. Story

> GSK, Shionogi HIV treatment wows analysts, beats Atripla in head-to-head. Item

> Biotech fundraising sours in a bleak first half. Article

Pharma News

 @FiercePharma: Judge chastises  for silence on AstraZeneca petition against generic Seroquel. Forced us into 'fire drill,' he says. Item | Follow @FiercePharma

> Don't look for Arena's Belviq to take Japan by storm, analysts say. Story

> Glaxo's new HIV combo trounces Gilead's Atripla. News

> New cancer drugs debut faster in U.S., but they cost more. More

Biomarkers News

> Counting eosinophils signpost survival in coronary artery disease. Item

> Colorectal cancer marker tags poor outcomes. Article

> Pronota biomarker test recognizes preeclampsia. Story

> Immune cells counted to predict survival after angioplasty. News

Drug Delivery News

> SRI gets Defense grant to develop oral-delivered MS drug. News

> QLT seeks options for eye drug delivery tech in major shakeup. Article

> Harvard docs use nanoparticles to get drugs to clotted arteries. Story

> Biotech builds IPO case on cancer drug delivery platform. Item

And Finally... China's requirement that any imported medical device must be approved in the nation where it is manufactured before it can be registered for sale on its home turf may be hurting U.S. manufacturing jobs in the industry, says Kem Hawkins, president of Cook Group. Story

Suggested Articles

Dexcom received a new European approval for its wearable continuous glucose monitor in pregnant women across Type 1, Type 2 and gestational diabetes.

Infectious disease blood tester Karius has raised $165 million led by SoftBank’s Vision Fund 2, the Japanese conglomerate’s sequel to its VC megafund.

BD will begin working with Babson Diagnostics to help bring its lab-quality device for collecting blood from capillaries into retail pharmacies.